A Daunting and Challenging Task to Prove the Effectiveness of Reducing Acute Exacerbation in COPD Patients with Type 2 Diabetes by GLP-1 Receptor Agonists

Am J Respir Crit Care Med. 2023 Dec 15;208(12):1345-1346. doi: 10.1164/rccm.202309-1671LE.

Authors

Qiumeng Li¹, Yating Chen¹, Hang Jiang¹, Yue Xi¹, Jiahe Wang¹, Xiaofeng Zhu¹, Jianxiong Lai¹, Nuofu Zhang¹, Dongxing Zhao¹

Affiliation

¹ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Sleep Medicine Center, Guangzhou Institute of Respiratory Health, National Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor / agonists
Glucagon-Like Peptide-1 Receptor Agonists
Humans
Hypoglycemic Agents / therapeutic use
Pulmonary Disease, Chronic Obstructive* / complications
Pulmonary Disease, Chronic Obstructive* / drug therapy

Substances

Glucagon-Like Peptide-1 Receptor Agonists
Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor

Grants and funding